Printer Friendly

Derma Sciences, Inc. receives market approval in the Philippines.

OLD FORGE, Pa.--(BUSINESS WIRE)--Aug. 20, 1996--DERMA SCIENCES, INC. (NASDAQ: DSCI) (BSE/PSE: DMS) today announced that the Republic of the Philippines has issued provisional Certificates of Product Registration (CPR) for its line of wound care products.

The approval grants a general clearance for six of the Company's products to be marketed and sold throughout the Philippines. The Company expects the final CPRs to be granted in the near future.

John T. Borthwick, President and Chief Executive Officer of DERMA SCIENCES, INC., stated that "This approval now clears the way for our partner, Inter-Health, Inc., to set up an official launch of our products. According to our contract dated April 1995, Inter-Health will begin to fulfill its obligations some time in the fourth quarter of 1996. The contract calls for minimum purchases of $358,000 over the next two years. The Philippine clearance represents the fourth foreign government approval for the Company's products behind Canada, Egypt and Indonesia."

Richard Stalbird, Director of International Business Development for DERMA SCIENCES, INC., stated "We are confident in Inter-Health's ability to capture its market and exceed the minimums associated with our contract."

DERMA SCIENCES, INC. is engaged in the research, development, marketing and sale of technology and products associated with tissue regeneration and the management of certain chronic non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. The Company markets its products through independent distributors, mainly to health care providers to the geriatric community such as nursing homes, similar extended care facilities, hospitals and home health care agencies throughout the United States. In addition, DERMA SCIENCES, INC. products are available in selected markets throughout the world through strategic alliances with local companies.

CONTACT: Derma Sciences, Inc., Old Forge

John Borthwick, (717) 457-1232

or

L. G. Zangani, Inc., Flemington, N.J.

Robert Moore, 908/788-9660; Fax: 908/788-4024

E-mail: Zangani@aol.com
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 20, 1996
Words:312
Previous Article:Greater Community Bancorp announces formation of Greater Community Financial, L.L.C. to provide full line of investment products to its clients.
Next Article:J. Ray McDermott S.A. names James L. Dutt interim chairman of the board and CEO.
Topics:


Related Articles
Derma Sciences Inc. announces product approvals by Ministry of Health in Indonesia; PT Tempo Scan Pacific places initial order.
DERMA SCIENCES, INC. ANNOUNCES CONTRACT WITH TRANS CANADERM INC. FOR DERMAGRAN II OINTMENT AND DERMAGRAN II SPRAY.
Derma Sciences launches products in Egypt.
DERMA SCIENCES, INC. RECEIVES LICENSE FROM EGYPTIAN MINISTRY OF HEALTH.
Derma Sciences, Inc. announces FDA 510(K) approval on a new Hydrogel as well as use-extensions on existing products.
Derma Sceinces, Inc. finalizes distribution agreement for South African region.
DERMA SCIENCES ELECTS FORMER MEDCHEM PRODUCTS CEO AS NEW CHAIRMAN.
Derma Sciences Closes $1.8 Million Private Placement.
Derma Sciences buys Genetic Laboratories.
Cleansing Foam.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters